Nathan Fowler

Professor Nathan Fowler is a Professor of Medicine at The University of Texas MD Anderson Cancer Center, Houston, US. Prof. Fowler completed his medical degree at The University of Texas Medical Branch at Galveston, Galveston, US, in 2001, following a BS in Biology at the University of Houston, Houston, US. He then undertook further postgraduate training at The University of Texas Medical Branch before becoming a Clinical Fellow at Georgetown University, Washington, US, in 2004 and Chief Fellow in 2006. In 2007, he took up an Assistant Professor position at the MD Anderson Cancer Center, before arriving at his current post.

Having helped develop some of the first protocols to use lenalidomide in chronic lymphocytic leukemia, the goal of his clinical research at the MD Anderson Cancer Center has been to further develop novel therapeutic regimens utilizing immunomodulatory agents to benefit patients with low grade non-Hodgkin lymphoma. He also serves as the chairman for many phase I and II trials for patients with non-Hodgkin lymphoma, including the largest clinical study to use immunomodulatory drugs for untreated low-grade lymphoma.

Positions of responsibility/awards:

• Member of the National Cancer Institute Follicular Lymphoma Sub Committee since 2013
• Member of the Southwest Oncology Group (SWOG) Lymphoma Steering Committee since 2013
• At the University of Texas MD Anderson Cancer Center he has been a member of the Credentials Committee of the Medical Staff since 2016, the Clinical Research Advisory Committee since 2012, and the Clinical Effectiveness Subcommittee since 2010
• Director of the Clinical Investigational and Translational Research Program, Department of Lymphoma/Myeloma, MD Anderson Cancer Center since 2012
• Team Lead for the Low-Grade Lymphoma Research Group since 2010 and the CNS Lymphoma Research Group since 2009 at the Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010–Present